Form 6-K BANCO BILBAO VIZCAYA For: May 08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2026
Commission file number: 1-10110
BANCO BILBAO VIZCAYA ARGENTARIA, S.A.
(Exact name of Registrant as specified in its charter)
BANK BILBAO VIZCAYA ARGENTARIA, S.A.
(Translation of Registrant’s name into English)
Calle Azul, 4
28050 Madrid
Spain
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
BANCO BILBAO VIZCAYA ARGENTARIA, S.A.
Explanatory Note
This Report on Form 6-K contains, as exhibits, certain documents listed below relating to the issuance and sale by Banco Bilbao Vizcaya Argentaria, S.A. (the “Issuer”) of U.S.$1,250,000,000 aggregate principal amount of 4.968% Senior Non-Preferred Fixed Rate Notes due 2031 (the “Notes”). This Report on Form 6-K and the Exhibits hereto are hereby incorporated by reference into the Registration Statement on Form F-3 (No. 333-289121) filed with the Securities and Exchange Commission.
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BANCO BILBAO VIZCAYA ARGENTARIA, S.A. | ||
| By: | /s/ Ignacio Echevarría Soriano | |
| Name: | Ignacio Echevarría Soriano | |
| Title: | Authorized Representative | |
Date: May 8, 2026
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pacific Empire Announces Second Tranche Closing of Non-Brokered Private Placement, Crew Mobilization to Camp, and Completion of Airborne Magnetic and Ground IP Surveys
- BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
- GondolaBio Announces Positive Phase 2a Results Demonstrating 79% Plasma Protoporphyrin IX Reduction and Disease-Modifying Potential of PORT-77 for Erythropoietic Protoporphyria
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share